Study samples for biomarkers in myotonic dystrophy
Part of Bones, joints & muscles, Brain & nervous system, Genetic & congenital clinical trials.
This study collects blood and, for some people, muscle tissue to look for signs (biomarkers) that can help track and better understand myotonic dystrophy. You may help by providing samples and basic muscle function testing, depending on your age and condition type.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with myotonic dystrophy type 1 (DM1) or type 2 (DM2), based on genetic testing and/or typical clinical features.
- You (or a guardian for minors) can give written informed consent (or the child can assent).
- If you are 5 or older, you may qualify for a one-time sample collection; if you have DM1 and are 14 or older, you may qualify for repeat testing.
- If you are between 18 and 65 years old, you may be eligible for muscle biopsy (tissue sample) as part of the study.
- You do not have certain health problems that raise risk, like immunosuppression, bleeding/clotting problems (coagulopathy), or known serious liver or kidney disease; you also cannot have HIV or hepatitis B/C.
- In the timeframe before sample collection or biopsy, you are not using certain blood-thinning medicines (anti-platelet in the last 7 days, or anticoagulants in the last 60 days).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks for tiny RNA “signals” in blood (and sometimes urine) and compares them with muscle samples in people with myotonic dystrophy (DM1 or DM2) and healthy controls. The goal is to find biomarkers that may help track the disease over time.
This study looks for signals in blood and other body fluids that may help track Duchenne or Becker muscular dystrophy. It may be helpful for patients by improving how future monitoring tests are developed.
This study uses MRI scans to measure muscle changes in people with myotonic dystrophy (DM1 or DM2) and healthy volunteers. The goal is to find better ways to track the disease over time.
This study is a long-term follow-up for people with myotonic dystrophy type 1. It aims to find better ways to measure how the disease progresses, which could help develop future treatments.
This study uses MRI scans and blood or other biomarkers to better understand muscular dystrophy in people with Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD). It may help researchers track disease changes and identify measurable markers over time.
This study looks at how to best measure muscle health and function in children with myotonic dystrophy. It may help prepare for future treatment trials.
Hear when a new Myotonic Dystrophy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.